AcariaHealth is proud to partner with Vertex Pharmaceuticals to bring forward a groundbreaking treatment option for individuals living with cystic fibrosis (CF): ALYFTREK™ (vanzacaftor/tezacaftor/deutivacaftor). This next-generation, once-daily CFTR modulator is now approved for patients aged 6 years and older who have at least one F508del mutation—or another CFTR gene mutation responsive to ALYFTREK™.

Together with Vertex, AcariaHealth is committed to delivering not only access to this innovative therapy but also compassionate, personalized support through our Foundation Care pharmacy to enhance the patient experience at every stage of their treatment journey.

What Makes ALYFTREK™ Different?
ALYFTREK™ represents a major advancement in the treatment of CF as the first once-daily CFTR modulator. Managing cystic fibrosis often requires multiple doses of medication throughout the day—frequently with fat-containing foods. ALYFTREK™ simplifies this routine, reducing the burden of treatment and allowing patients to focus more on living life, not managing it.

This therapy is especially impactful for a subset of approximately 150 individuals in the U.S. who carry one of 31 specific mutations—patients who, until now, had no access to CFTR modulators. For them, ALYFTREK™ offers a transformative opportunity to improve their health and daily life.

A Closer Look at Cystic Fibrosis
Cystic fibrosis is a rare, life-limiting genetic disease that affects more than 92,000 people worldwide. It impacts multiple organ systems, including the lungs, liver, pancreas, and digestive tract. The condition stems from mutations in the CFTR gene, which impair the function of the CFTR protein. This leads to the buildup of thick, sticky mucus in the lungs and other organs, causing persistent lung infections and progressive respiratory damage.

While CF remains a challenging disease, the emergence of therapies like ALYFTREK™ offers new hope—improving outcomes and significantly enhancing quality of life for many patients.

Supporting Patients Every Step of the Way
At Foundation Care, an AcariaHealth Solution, we are deeply committed to supporting the cystic fibrosis community. We understand the complexity of CF and the dedication it takes to manage it every day. That’s why we provide expert guidance, personalized support, and reliable service to patients and their care teams.

Our experienced pharmacists and clinicians work closely with each patient to ensure seamless access to treatment, ongoing support, and the best possible outcomes. From prescription to delivery, we are your trusted partner in CF care.

Learn More
For full prescribing information and resources, visit:

• alyftrek.com – For patients and families
• alyftrekhcp.com – For healthcare professionals

Stay informed on the latest advancements in cystic fibrosis care by following AcariaHealth on LinkedIn.